<DOC>
	<DOC>NCT00896233</DOC>
	<brief_summary>This study will assess the repeatability of Magnetic Resonance Elastography (MRE) in both healthy volunteers and Hepatitis C Virus (HCV)-infected patients with fibrosis and lay the groundwork for the validation of MRE as an alternative to liver biopsy.</brief_summary>
	<brief_title>Magnetic Resonance Elastography for Assessment of Liver Fibrosis (MK-0000-132)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Male or female and at least 18 years of age Generally good health Willing to fast for 8 hours prior to each study visit Hepatitis C Virus (HCV) Positive serology for HCV and detectable HCV ribonucleic acid (RNA) in blood within 12 weeks of screening; For Part I, known fibrosis stage of at least =F2 (METAVIR) or =F3 (Ishak) from biopsy performed within 3 months of screening; For Part 2, known fibrosis stage of F1F4 (METAVIR) or F1F6 (Ishak) Never been treated for HCV Healthy Participant Documented absence of hepatitis B virus, HCV, acute hepatitis A virus, and human immunodeficiency virus (HIV) within 12 weeks of screening History of stroke, seizures, or neurological disorders Consumption of excessive amounts of alcohol Use of products containing nicotine Unable to hold a breath for 20 seconds Claustrophobia Use of illicit drugs or history of drug or alcohol abuse HCVPositive Evidence or history of chronic hepatitis not caused by HCV HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Staging of liver fibrosis prior to clinical trials for treatment of Hepatitis C Virus</keyword>
</DOC>